NCT06852079RecruitingPhase 3
Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan
Source: ClinicalTrials.gov · Last updated 28 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline. 2. Type, frequency and severity of ADRs during the study period. Secondary End Points: 1\. Compliance of the prescribed study medication.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 119 (estimated)
- First submitted
- 24 Feb 2025
- Start date
- 23 Dec 2023
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Abdul Bari
- Diseases
- High blood pressure
- NCT number
- NCT06852079
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 119
- From 23 Dec 2023 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with recent history of following will be excluded:
- Severe hypertension,
- Congestive cardiac failure,
- Left ventricular failure,
- Myocardial ischemia,
- Renal failure or
- Cerebrovascular accidents
Who the study is looking for
- Ability to sign ICD
- Participant(s) are willing and able to fulfill the requirements of the study protocol
- Mild to moderate hypertensive
- Mild hypertension range (140-159/90-99 mm Hg)
- Moderate hypertension range (160-179/100-109 mm Hg)
- Be between the age of 30 to 60 year
Age in the registry: 30 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Taj Medical Complex, Hamdard University Hospital Coordinator of this site? Confirm its status | Karachi | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.